Chimiothérapie intensive et autogreffe de cellules souches hématopoïétiques dans les tumeurs germinales

Christophe Massard; Aude Fléchon; Karim Fizazi; Jean Pierre Droz

doi:10.1684/bdc.2011.1406

Chimiothérapie intensive et autogreffe de cellules souches hématopoïétiques dans les tumeurs germinales

Translated title of the contribution: High dose chemotherapy and germ cell tumor

Christophe Massard, Aude Fléchon, Karim Fizazi, Jean Pierre Droz

Research output: Contribution to journal › Review article › peer-review

Abstract

Germ cell tumors are cured by cisplatin-based chemotherapy and secondary surgery. Patients with initial poor response to chemotherapy and relapsed disease patients have poor prognosis. Among different therapeutic approaches high dose chemotherapy with hematopoietic stem cell support has been studied. Despite the existence of a number of phase II trials and several wellconducted phase III trials, this approach is neither a standard nor an option in the setting of first line and first salvage treatment. A randomized phase III trial has recently been initiated and patients with relapsed disease should be offered to participate in the trial. Several selected indications could be discussed in further lines of treatment.

Translated title of the contribution	High dose chemotherapy and germ cell tumor
Original language	French
Pages (from-to)	945-949
Number of pages	5
Journal	Bulletin du Cancer
Volume	98
Issue number	8
DOIs	https://doi.org/10.1684/bdc.2011.1406
Publication status	Published - 1 Jan 2011

Access to Document

10.1684/bdc.2011.1406

Cite this

@article{525215e03104498faa058a108d6f9323,

title = "Chimioth{\'e}rapie intensive et autogreffe de cellules souches h{\'e}matopo{\"i}{\'e}tiques dans les tumeurs germinales",

abstract = "Germ cell tumors are cured by cisplatin-based chemotherapy and secondary surgery. Patients with initial poor response to chemotherapy and relapsed disease patients have poor prognosis. Among different therapeutic approaches high dose chemotherapy with hematopoietic stem cell support has been studied. Despite the existence of a number of phase II trials and several wellconducted phase III trials, this approach is neither a standard nor an option in the setting of first line and first salvage treatment. A randomized phase III trial has recently been initiated and patients with relapsed disease should be offered to participate in the trial. Several selected indications could be discussed in further lines of treatment.",

keywords = "First line treatment, Germ cell tumor, High dose chemotherapy, Prognostic factors, Randomized trials, Salvage treatment",

author = "Christophe Massard and Aude Fl{\'e}chon and Karim Fizazi and Droz, {Jean Pierre}",

year = "2011",

month = jan,

day = "1",

doi = "10.1684/bdc.2011.1406",

language = "Fran{\c c}ais",

volume = "98",

pages = "945--949",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "8",

}

TY - JOUR

T1 - Chimiothérapie intensive et autogreffe de cellules souches hématopoïétiques dans les tumeurs germinales

AU - Massard, Christophe

AU - Fléchon, Aude

AU - Fizazi, Karim

AU - Droz, Jean Pierre

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Germ cell tumors are cured by cisplatin-based chemotherapy and secondary surgery. Patients with initial poor response to chemotherapy and relapsed disease patients have poor prognosis. Among different therapeutic approaches high dose chemotherapy with hematopoietic stem cell support has been studied. Despite the existence of a number of phase II trials and several wellconducted phase III trials, this approach is neither a standard nor an option in the setting of first line and first salvage treatment. A randomized phase III trial has recently been initiated and patients with relapsed disease should be offered to participate in the trial. Several selected indications could be discussed in further lines of treatment.

AB - Germ cell tumors are cured by cisplatin-based chemotherapy and secondary surgery. Patients with initial poor response to chemotherapy and relapsed disease patients have poor prognosis. Among different therapeutic approaches high dose chemotherapy with hematopoietic stem cell support has been studied. Despite the existence of a number of phase II trials and several wellconducted phase III trials, this approach is neither a standard nor an option in the setting of first line and first salvage treatment. A randomized phase III trial has recently been initiated and patients with relapsed disease should be offered to participate in the trial. Several selected indications could be discussed in further lines of treatment.

KW - First line treatment

KW - Germ cell tumor

KW - High dose chemotherapy

KW - Prognostic factors

KW - Randomized trials

KW - Salvage treatment

UR - http://www.scopus.com/inward/record.url?scp=80052564379&partnerID=8YFLogxK

U2 - 10.1684/bdc.2011.1406

DO - 10.1684/bdc.2011.1406

M3 - Article 'review'

AN - SCOPUS:80052564379

SN - 0007-4551

VL - 98

SP - 945

EP - 949

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 8

ER -

Chimiothérapie intensive et autogreffe de cellules souches hématopoïétiques dans les tumeurs germinales

Abstract

Access to Document

Other files and links

Cite this